• Bicycle Therapeutics PLC BCYC.OQ reported a quarterly adjusted loss of 74 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.26. The mean expectation of thirteen analysts for the quarter was for a loss of 78 cents per share. Wall Street expected results to range from $-1.05 to -54 cents per share.

• Revenue fell 50% to $2.68 million from a year ago; analysts expected $6.84 million.

• Bicycle Therapeutics PLC's reported EPS for the quarter was a loss of 74 cents​.

• The company reported a quarterly loss of $50.8 million.

• Bicycle Therapeutics PLC shares had risen by 6.2% this quarter and gained 32.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 33.3% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Bicycle Therapeutics PLC is 38.00

This summary was machine generated from LSEG data November 1 at 03:42 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)